Literature DB >> 20978130

Cancer-associated p53 tetramerization domain mutants: quantitative analysis reveals a low threshold for tumor suppressor inactivation.

Rui Kamada1, Takao Nomura, Carl W Anderson, Kazuyasu Sakaguchi.   

Abstract

The tumor suppressor p53, a 393-amino acid transcription factor, induces cell cycle arrest and apoptosis in response to genotoxic stress. Its inactivation via the mutation of its gene is a key step in tumor progression, and tetramer formation is critical for p53 post-translational modification and its ability to activate or repress the transcription of target genes vital in inhibiting tumor growth. About 50% of human tumors have TP53 gene mutations; most are missense ones that presumably lower the tumor suppressor activity of p53. In this study, we explored the effects of known tumor-derived missense mutations on the stability and oligomeric structure of p53; our comprehensive, quantitative analyses encompassed the tetramerization domain peptides representing 49 such substitutions in humans. Their effects on tetrameric structure were broad, and the stability of the mutant peptides varied widely (ΔT(m) = 4.8 ∼ -46.8 °C). Because formation of a tetrameric structure is critical for protein-protein interactions, DNA binding, and the post-translational modification of p53, a small destabilization of the tetrameric structure could result in dysfunction of tumor suppressor activity. We suggest that the threshold for loss of tumor suppressor activity in terms of the disruption of the tetrameric structure of p53 could be extremely low. However, other properties of the tetramerization domain, such as electrostatic surface potential and its ability to bind partner proteins, also may be important.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20978130      PMCID: PMC3012982          DOI: 10.1074/jbc.M110.174698

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  55 in total

Review 1.  p53 and human cancer: the first ten thousand mutations.

Authors:  P Hainaut; M Hollstein
Journal:  Adv Cancer Res       Date:  2000       Impact factor: 6.242

Review 2.  The p53 mutation "gradient effect" and its clinical implications.

Authors:  Gerard P Zambetti
Journal:  J Cell Physiol       Date:  2007-11       Impact factor: 6.384

3.  The oligomerization domain of p53: crystal structure of the trigonal form.

Authors:  M Miller; J Lubkowski; J K Rao; A T Danishefsky; J G Omichinski; K Sakaguchi; H Sakamoto; E Appella; A M Gronenborn; G M Clore
Journal:  FEBS Lett       Date:  1996-12-09       Impact factor: 4.124

4.  The human homologs of checkpoint kinases Chk1 and Cds1 (Chk2) phosphorylate p53 at multiple DNA damage-inducible sites.

Authors:  S Y Shieh; J Ahn; K Tamai; Y Taya; C Prives
Journal:  Genes Dev       Date:  2000-02-01       Impact factor: 11.361

Review 5.  The role of tetramerization in p53 function.

Authors:  P Chène
Journal:  Oncogene       Date:  2001-05-10       Impact factor: 9.867

6.  Oxygen sensitivity severely limits the replicative lifespan of murine fibroblasts.

Authors:  Simona Parrinello; Enrique Samper; Ana Krtolica; Joshua Goldstein; Simon Melov; Judith Campisi
Journal:  Nat Cell Biol       Date:  2003-08       Impact factor: 28.824

7.  Understanding the function-structure and function-mutation relationships of p53 tumor suppressor protein by high-resolution missense mutation analysis.

Authors:  Shunsuke Kato; Shuang-Yin Han; Wen Liu; Kazunori Otsuka; Hiroyuki Shibata; Ryunosuke Kanamaru; Chikashi Ishioka
Journal:  Proc Natl Acad Sci U S A       Date:  2003-06-25       Impact factor: 11.205

8.  Refined solution structure of the oligomerization domain of the tumour suppressor p53.

Authors:  G M Clore; J Ernst; R Clubb; J G Omichinski; W M Kennedy; K Sakaguchi; E Appella; A M Gronenborn
Journal:  Nat Struct Biol       Date:  1995-04

Review 9.  p53 polymorphisms: cancer implications.

Authors:  Catherine Whibley; Paul D P Pharoah; Monica Hollstein
Journal:  Nat Rev Cancer       Date:  2009-02       Impact factor: 60.716

10.  Regulation of p53 tetramerization and nuclear export by ARC.

Authors:  Roger S-Y Foo; Young-Jae Nam; Marc Jason Ostreicher; Mark D Metzl; Russell S Whelan; Chang-Fu Peng; Anthony W Ashton; Weimin Fu; Kartik Mani; Suet-Feung Chin; Elena Provenzano; Ian Ellis; Nichola Figg; Sarah Pinder; Martin R Bennett; Carlos Caldas; Richard N Kitsis
Journal:  Proc Natl Acad Sci U S A       Date:  2007-12-17       Impact factor: 11.205

View more
  19 in total

1.  C-terminal region of human p53 attenuates buffalo p53 N-terminal-specific transactivation of p21 promoter by modulating tetramerization of the protein.

Authors:  Minu Singh; Tapas Mukhopadhyay
Journal:  Mol Cell Biochem       Date:  2017-11-16       Impact factor: 3.396

Review 2.  Mutant TP53 posttranslational modifications: challenges and opportunities.

Authors:  Thuy-Ai Nguyen; Daniel Menendez; Michael A Resnick; Carl W Anderson
Journal:  Hum Mutat       Date:  2014-02-11       Impact factor: 4.878

3.  Structure-based predictions broadly link transcription factor mutations to gene expression changes in cancers.

Authors:  Justin Ashworth; Brady Bernard; Sheila Reynolds; Christopher L Plaisier; Ilya Shmulevich; Nitin S Baliga
Journal:  Nucleic Acids Res       Date:  2014-11-05       Impact factor: 16.971

4.  Molecular Characterization of the Tumor Microenvironment in Renal Medullary Carcinoma.

Authors:  David S Tourigny; Mark Zucker; Minsoo Kim; Paul Russo; Jonathan Coleman; Chung-Han Lee; Maria I Carlo; Ying-Bei Chen; A Ari Hakimi; Ritesh R Kotecha; Ed Reznik
Journal:  Front Oncol       Date:  2022-06-28       Impact factor: 5.738

5.  A Rare TP53 Mutation Predominant in Ashkenazi Jews Confers Risk of Multiple Cancers.

Authors:  Jacquelyn Powers; Emilia M Pinto; Thibaut Barnoud; Jessica C Leung; Tetyana Martynyuk; Andrew V Kossenkov; Aaron H Philips; Heena Desai; Ryan Hausler; Gregory Kelly; Anh N Le; Marilyn M Li; Suzanne P MacFarland; Louise C Pyle; Kristin Zelley; Katherine L Nathanson; Susan M Domchek; Thomas P Slavin; Jeffrey N Weitzel; Jill E Stopfer; Judy E Garber; Vijai Joseph; Kenneth Offit; Jill S Dolinsky; Stephanie Gutierrez; Kelly McGoldrick; Fergus J Couch; Brooke Levin; Morris C Edelman; Carolyn Fein Levy; Sheri L Spunt; Richard W Kriwacki; Gerard P Zambetti; Raul C Ribeiro; Maureen E Murphy; Kara N Maxwell
Journal:  Cancer Res       Date:  2020-07-16       Impact factor: 12.701

6.  The curcumin analog HO-3867 selectively kills cancer cells by converting mutant p53 protein to transcriptionally active wildtype p53.

Authors:  Esha Madan; Taylor M Parker; Matthias R Bauer; Alisha Dhiman; Christopher J Pelham; Masaki Nagane; M Lakshmi Kuppusamy; Matti Holmes; Thomas R Holmes; Kranti Shaik; Kevin Shee; Salome Kiparoidze; Sean D Smith; Yu-Soon A Park; Jennifer J Gomm; Louise J Jones; Ana R Tomás; Ana C Cunha; Karuppaiyah Selvendiran; Laura A Hansen; Alan R Fersht; Kálmán Hideg; Rajan Gogna; Periannan Kuppusamy
Journal:  J Biol Chem       Date:  2018-01-30       Impact factor: 5.157

7.  Further evidence for pathogenicity of the TP53 tetramerization domain mutation p.Arg342Pro in Li-Fraumeni syndrome.

Authors:  Anna Etzold; Julia C Schröder; Oliver Bartsch; Ulrich Zechner; Danuta Galetzka
Journal:  Fam Cancer       Date:  2015-03       Impact factor: 2.375

8.  Parkinson-causing α-synuclein missense mutations shift native tetramers to monomers as a mechanism for disease initiation.

Authors:  Ulf Dettmer; Andrew J Newman; Frank Soldner; Eric S Luth; Nora C Kim; Victoria E von Saucken; John B Sanderson; Rudolf Jaenisch; Tim Bartels; Dennis Selkoe
Journal:  Nat Commun       Date:  2015-06-16       Impact factor: 14.919

9.  Genomic profiling of multiple sequentially acquired tumor metastatic sites from an "exceptional responder" lung adenocarcinoma patient reveals extensive genomic heterogeneity and novel somatic variants driving treatment response.

Authors:  Romi Biswas; Shaojian Gao; Constance M Cultraro; Tapan K Maity; Abhilash Venugopalan; Zied Abdullaev; Alexey K Shaytan; Corey A Carter; Anish Thomas; Arun Rajan; Young Song; Stephanie Pitts; Kevin Chen; Sara Bass; Joseph Boland; Ken-Ichi Hanada; Jinqiu Chen; Paul S Meltzer; Anna R Panchenko; James C Yang; Svetlana Pack; Giuseppe Giaccone; David S Schrump; Javed Khan; Udayan Guha
Journal:  Cold Spring Harb Mol Case Stud       Date:  2016-11

10.  Fuse binding protein antagonizes the transcription activity of tumor suppressor protein p53.

Authors:  Updesh Dixit; Zhihe Liu; Ashutosh K Pandey; Ramesh Kothari; Virendra N Pandey
Journal:  BMC Cancer       Date:  2014-12-08       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.